WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US.
This is WuXi STA’s second facility in the US and will provide expanded capacity and greater flexibility to meet the requirements of the company’s customers in the US and the world.
Go deeper with GlobalData
WuXi STA is a contract research, development, and manufacturing organisation (CRDMO) in Delaware.
Situated in the Middletown Business Center at 1091 Industrial Drive, the facility will generate almost 500 full-time jobs by 2026.
The first phase of the new campus will offer formulation development, clinical and commercial drug product manufacturing services for various oral and injectable dosage forms. It will also provide packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.
See Also:
The WuXi STA Middletown facility is anticipated to start operations in 2025.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataDelaware Governor John Carney said: “Over the next five years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities, bringing with it good jobs and economic growth. This campus is only possible because of Delaware’s world-class, innovative workforce..”
WuXi AppTec co-CEO and WuXi STA CEO Dr. Minzhang Chen said: “WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.”
WuXi STA has 12 locations across the US, Europe and Asia that offer a range of services.
Along with three other drug product manufacturing sites in Couvet (Switzerland), Wuxi City (China) and Shanghai (China), this new facility is expected to boost the company’s drug production capacity and capabilities.
———————————————————————————————————————
Image: Ground being broken of the WuXi STA Middletown campus. Credit: WuXi AppTec /PRNewswire.
